No Data
No Data
No Data
No Data
No Data
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with
GlobeNewswireApr 24 19:00
Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis
Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic a
BenzingaApr 18 19:11
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
—"Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis" Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—
GlobeNewswireApr 2 19:00
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) today reported that the European Patent Office has granted a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation.
GlobeNewswireMar 25 19:06
Oppenheimer Maintains Perform on Chemomab Therapeuticsto Perform
Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics from Perform to Perform.
Analyst UpgradesMar 8 21:45
Chemomab Therapeutics Q4 EPS $(0.26) Up From $(0.72) YoY
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.26) per share. This is a 63.89 percent increase over losses of $(0.72) per share from the same period last year.
BenzingaMar 7 20:06
No Data
No Data